This statistic displays the share of children between *** and nine years who are obese in Europe from 2015 to 2017, by gender . In this period, **** percent of girls and boys in Denmark were obese.

By 2025, the prevalence of obese women in the United Kingdom is projected to be at ** percent, this would be the highest obesity prevalence in women compared to EU countries. Ireland with **** percent was forecast to have the second highest prevalence of obese women in Europe, followed by Malta at ** percent.

As of 2024, approximately ** percent of men and ** percent of women in Romania considered themselves overweight or obese. Across the European countries featured, being overweight or obese was more prevalent among males.

Introduction: Using data from the TackSHS survey, we aim to provide updated estimates on the prevalence and determinants of overweight and obesity in Europe. Methods: A face-to-face survey was conducted in 2017-2018 in 12 European countries (Bulgaria, England, France, Germany, Greece, Ireland, Italy, Latvia, Poland, Portugal, Romania, and Spain). Overall, 10,810 participants, representative in each country of the general adult population, provided information on self-reported height and weight. Results: Almost half of participants (48.1%; 95% confidence interval, CI: 47.2-49.1) reported to be overweight or obese (54.1% in men and 42.5% in women), and 12.6% (95% CI: 12.0-13.2) obese (11.3% in men and 13.8% in women). Obesity prevalence was lowest in Italy (7.5%) and France (8.8%), and highest in Greece (19.7%) and Romania (21.1%). Multilevel logistic random-effects analyses showed that prevalence of obesity was related with higher age and lower level of education and socioeconomic status. As compared to northern European countries, Western and Southern European ones showed a significantly lower obesity prevalence. When compared to a companion study conducted in 2010, Eastern and Northern European countries showed an increased trend in obesity prevalence. Conversely, countries with the lowest obesity prevalence (less than 10%), such as Italy and France, showed a decreased trend. Conclusions: Despite a large heterogeneity across countries, overweight and obesity prevalence estimates in Europe are alarming, with most of the countries reporting obesity prevalence approaching 20% or more, particularly in Eastern and Northern Europe. Since 2010, obesity prevalence increased in most of these countries.

This statistis displays the growth in obesity rates in selected European countries in 1975 and 2014. The obesity rate in Ireland grew from *** percent in 1975 to **** percent in 2014.

Introduction: Obesity constitutes a major public health problem in Europe, but how the obesity epidemic in European countries will evolve remains unknown. Most previous obesity projections considered the short-term future only, focused on single non-European countries, and projected ongoing increases foremost. We comparatively project obesity prevalence into the long-term future for 18 European countries and the USA. Data: We used national age-specific (20–84 years) and sex-specific obesity prevalence estimates (1975–2016) from the NCD Risk Factor Collaboration (NCD-RisC) 2017 study, which are based on available measured height and weight data, supplemented with estimates from a Bayesian hierarchical model. Methods: We projected age- and sex-specific obesity prevalence up to the year 2100 by integrating the notion of a wave-shaped obesity epidemic into conventional age-period projections. Results: In 1990–2016, the increasing trends in obesity prevalence were decelerating. Obesity is expected to reach maximum levels between 2030 and 2052 among men, and between 2026 and 2054 among women. The maximum levels will likely be reached first in The Netherlands, USA, and UK, and last in Switzerland; and are expected to be highest in the USA and UK, and lowest in The Netherlands for men and Denmark for women. In 2060, obesity prevalence is expected to be lowest among Dutch men and highest among Swiss men. The projected age-specific obesity prevalence levels have an inverse U-shape, peaking at around the age of 60–69 years. Discussion: Applying our novel approach to the NCD-RisC 2017 data, obesity prevalence is expected to reach maximum levels between 2026 and 2054, with the USA and UK reaching the highest maximum levels first, followed by other European countries.

The size of the Weight Loss Surgery Market in Europe market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 15.00% during the forecast period. Recent developments include: In June 2022, Rhythm Pharmaceuticals, Inc. announced that IMCIVREE is available to patients in Germany.The European Commission granted IMCIVREE marketing authorization for the treatment of obesity and the management of hunger in adults and children aged 6 and older with genetically confirmed loss-of-function biallelic pro-opiomelanocortin, including proprotein convertase subtilisin/kexin type 1 deficiency or biallelic leptin receptor deficiency., In June 2022, European Medicines Agency (EMA) safety committee Pharmacovigilance Risk Assessment Committee (PRAC) has recommended the withdrawal of European Union (EU) marketing authorisations for amfepramone obesity medicines.. Key drivers for this market are: Increase in Obese Population, Prevalence of Diabetes and Heart Diseases; Government Initiatives to Curb Obesity; Insurance Coverage of Surgeries. Potential restraints include: Lack of Knowledge and Awareness in the Region, High Cost of Surgery. Notable trends are: Gastric Balloons Segment is Expected to Witness the Highest CAGR in the Market Over the Forecast Period.

Europe Obesity Management Market growth is driven by rising obesity rates, technological advancements, and supportive government initiatives.

BackgroundThe comorbidities associated with overweight and obesity have been well researched and scientifically proven while their relationship to mental health is still not verified.MethodsThis study is aimed at investigating reciprocal associations between obesity and mental health, and is intended to further analyze possible long-term effects using data from the Survey of Health, Ageing and Retirement in Europe (SHARE). In order to do that, waves 4 and 8, conducted in 2010 and 2019/20 of this survey, were analyzed in a cross-lagged panel approach including 16,184 adult Europeans (50+) using multiple linear regression analysis focusing on the Body Mass Index (BMI), depression status and quality of life (QoL).ResultsFindings yield significant cross-lagged effects in one direction regarding BMI predicting QoL and depression state, whereas depression state and QoL do not significantly predict BMI. Findings include people living with obesity, overweight, and underweight showing significantly decreased levels of QoL as well as increased depression scores compared to people of normal weight over a lag time of 10 years, where people living with obesity indicate the strongest effect.ConclusionsHowever, results do not confirm reciprocal associations in the long term. Hence, there is a strong need to carry out further research on this issue.

By 2030, Malta, Hungary, and the United Kingdom were projected to have the highest prevalence of obesity in their populations among men in Europe. Across the whole of Europe, approximately ** percent of men were forecast to be classified as obese in 2030.

Background: Obesity is a risk factor for many chronic diseases and the prevalence is increasing worldwide. Research suggests that sedentary behaviour (sitting) may be related to obesity. Aim: To examine the association between sitting time and obesity, while controlling for physical activity, in a large international sample. Subjects and methods: In total, 5338 adults from the UK, USA, Germany, Spain, Italy, France, Portugal, Austria and Switzerland self-reported their total daily sitting time, physical activity, age, height and weight. BMI (kg/m2), total physical activity (MET-minutes/week) and sitting time (hours/day) were derived. Participants were grouped into quartiles based on their daily sitting time (<4, 4–≤6, 6–≤8 and >8 hours/day) and logistic regression models explored the odds of being obese vs normal weight for each sitting time quartile. Results: Participants in the highest sitting time quartile (≥8 hours/day) had 62% higher odds of obesity compared to participants in the lowest quartile (<4 hours/day) after adjustment for physical activity and other confounding variables (OR = 1.62, 95% CI = 1.24–2.12, p < .01). Conclusion: Sitting time is associated with obesity in adults, independent of physical activity. Future research should clarify this association using objective measures of sitting time and physical activity to further inform health guidelines.

Historical dataset showing European Union obesity rate by year from N/A to N/A.

Europe Obesity Intervention Devices market USD 76.86 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031. Increasing obesity rates and a rising emphasis on preventive healthcare is expected to aid the sales to USD 109.4 million by 2031

Life course data on obesity may enrich the quality of epidemiologic studies analysing health consequences of obesity. However, achieving such data may require substantial resources.We investigated the use of body silhouettes in adults as a tool to reflect obesity in the past. We used large population-based samples to analyse to what extent self-reported body silhouettes correlated with the previously measured (9–23 years) body mass index (BMI) from both measured (European Community Respiratory Health Survey, N = 3 041) and self-reported (Respiratory Health In Northern Europe study, N = 3 410) height and weight. We calculated Spearman correlation between BMI and body silhouettes and ROC-curve analyses for identifying obesity (BMI ≥30) at ages 30 and 45 years. Spearman correlations between measured BMI age 30 (±2y) or 45 (±2y) and body silhouettes in women and men were between 0.62–0.66 and correlations for self-reported BMI were between 0.58–0.70. The area under the curve for identification of obesity at age 30 using body silhouettes vs previously measured BMI at age 30 (±2y) was 0.92 (95% CI 0.87, 0.97) and 0.85 (95% CI 0.75, 0.95) in women and men, respectively; for previously self-reported BMI, 0.92 (95% CI 0.88, 0.95) and 0.90 (95% CI 0.85, 0.96). Our study suggests that body silhouettes are a useful epidemiological tool, enabling retrospective differentiation of obesity and non-obesity in adult women and men.

Europe Anti Obesity Drugs market size was $1,671.59 Million in 2024 and it is forecasted to reach $7,631.62 Million by 2030. Anti Obesity Drugs Industry's Compound Annual Growth Rate was 29.45% from 2024 to 2031.

Europe Obesity & Metabolic Syndrome Management Market is projected to grow around USD 6.5 billion in 2025 to USD 13.2 billion by 2031, at a CAGR of 12.2%.

This indicator is derived from the body mass index (BMI), which is defined as the weight in kilograms divided by the square of the height in metres. People aged 18 years or over are considered obese if their BMI is equal to or greater than 30. The category ‘pre-obese’ refers to people with a BMI between 25 and less than 30. The category ‘overweight’ (BMI equal or greater than 25) combines the two categories pre-obese and obese. The data presented in this section stem from the European Health Interview Survey (EHIS) and the EU Statistics on Income and Living Conditions (EU-SILC).

This statistic displays the obesity prevalence in selected European countries by 2025. Great Britain is set to be the most obese nation in Europe by 2025 with an obesity prevalence of **** percent, followed closely by Ireland and Lithuania with an expected prevalence rate of ***** percent respectively.

Overweight and obesity prevalence rates estimates (1975-2016)

The indicator measures the share of obese people based on their body mass index (BMI). BMI is defined as the weight in kilos divided by the square of the height in meters. People aged 18 years or over are considered obese with a BMI equal or greater than 30. Other categories are: underweight (BMI less than 18.5), normal weight (BMI between 18.5 and less than 25), and pre-obese (BMI between 25 and less than 30). The category overweight (BMI equal or greater than 25) combines the two categories pre-obese and obese.